MedTrace Logo

Proton Radiation Therapy for Macular Degeneration

NCT01833325 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2018-02-23

No results posted yet for this study

Summary

This is a pilot study to determine if proton radiation therapy can provide effective and safe treatment for subfoveal neovascularization membrane (SNVM). The study will include adult patients over the age of 50 with macular degeneration, who have subfoveal neovascularization membrane (SNVM) and have had prior treatment with Avastin or Lucentis. Additional purposes of this study are to see if the growth of neovascular membranes can be stopped and overall vision improved with the use of protons and assess the side effects associated with this treatment.

Conditions

  • Age-Related Macular Degeneration

Interventions

RADIATION

Proton radiation

Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Roi Dagan, MD, · University of Florida Proton Therapy Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01833325 on ClinicalTrials.gov